Breaking Down Cryo-Cell International, Inc. (CCEL) Financial Health: Key Insights for Investors

Are you keeping a close watch on Cryo-Cell International, Inc. (CCEL) and wondering about its financial stability? For the fiscal year 2024, the company reported consolidated revenues of $32.0 million, a slight increase from $31.3 million in 2023. But, is that all there is to the story? What about their profitability, and how do changes in tax regulations affect their bottom line? In 2024, Cryo-Cell announced a net income of $402,000 ($0.05 per share), a significant turnaround from a net loss of $9.5 million in 2023. How sustainable is this recovery, and what factors are contributing to it? Keep reading to explore these key financial insights and understand what they mean for investors.

Cryo-Cell International, Inc. (CCEL) Revenue Analysis

Cryo-Cell International, Inc. (CCEL) primarily generates revenue through the cryopreservation of umbilical cord blood and umbilical cord tissue. These services cater to parents who wish to store their newborn's stem cells for potential future medical use. The company operates mainly in the family banking sector, focusing on direct-to-consumer marketing and sales efforts.

Analyzing Cryo-Cell International, Inc.'s revenue streams involves looking at historical data to discern trends in year-over-year growth. According to the data available, Cryo-Cell International's total revenues for the year ended November 30, 2024, were $34.9 million, an increase of $1.4 million or 4.2%, compared to $33.5 million for the year ended November 30, 2023. The increase in revenue was primarily due to an increase in processing and storage fees.

Here's a summary of the key factors influencing Cryo-Cell International, Inc.'s revenue:

• Processing and Storage Fees: These constitute the bulk of Cryo-Cell's revenue.
• Geographic Focus: Predominantly United States, with some international presence.
• Marketing Strategies: Direct-to-consumer approach impacts enrollment rates and revenue.

For a more detailed understanding of Cryo-Cell International, Inc.'s values, refer to: Mission Statement, Vision, & Core Values of Cryo-Cell International, Inc. (CCEL).

To provide a clearer picture, below is a summarized table showing the revenue changes:

Notably, Cryo-Cell International, Inc. has experienced fluctuations in its revenue streams influenced by market conditions, competition, and its strategic initiatives. Investors should monitor these factors closely to assess the company's financial health and growth potential.

Cryo-Cell International, Inc. (CCEL) Profitability Metrics

Analyzing Cryo-Cell International, Inc.'s profitability involves looking at several key metrics that provide insights into the company's financial health and operational efficiency. These include gross profit, operating profit, and net profit margins, as well as trends and comparisons with industry averages.

For the fiscal year ended November 30, 2024, Mission Statement, Vision, & Core Values of Cryo-Cell International, Inc. (CCEL)., Cryo-Cell International reported a net income of $402,000, or $0.05 per basic and diluted share, a significant improvement compared to a net loss of $9.5 million, or $1.14 per basic and diluted share, for fiscal year 2023 [1, 2]. Consolidated revenues for fiscal year 2024 were $32.0 million, up from $31.3 million in fiscal year 2023 [2, 9].

Here's a breakdown of Cryo-Cell International's profitability metrics:

• Gross Profit: According to Simply Wall St, the gross profit for CCEL was $24.1 million [3].
• Gross Profit Margin: YCharts data shows a gross profit margin of 79.60% for the quarter ended November 30, 2024 [5]. AASTOCKS.com reported the gross profit margin at 75.15% for the fiscal year ending November 2024, showing an increasing trend from previous years [4]. Morningstar reported a gross profit margin of 73.07% [11].
• Operating Profit: Morningstar data shows an operating income of $7.01 million [11].
• Operating Profit Margin: AASTOCKS.com reported an operating profit margin of 11.85% for the year ended November 2024 [4]. GuruFocus data shows an operating margin of -1.53% for the quarter that ended in November 2024 [6].
• Net Income: The company reported a net income of $402,000 in fiscal year 2024, a considerable improvement from the net loss of $9.5 million in fiscal year 2023 [2].
• Net Profit Margin: Simply Wall St. indicates a net profit margin of 0.40% [3]. CSIMarket shows a net margin of 1.26% [13]. Yahoo Finance reports a profit margin of 0.40% [27].

Here is a table summarizing the profitability ratios over the recent years [4]:

In Q1 2025, the company's revenue increased to $7.97 million from $7.85 million in Q1 2024. However, net income decreased to $283,000 ($0.03 per share) compared to $556,000 ($0.07 per share) in the same period last year [7, 8, 10, 12].

The increase in revenue for fiscal year 2024 was primarily driven by a rise in processing and storage fee revenue, which amounted to $31.6 million, compared to $30.8 million in the previous year [2, 9]. The company also saw gains on marketable securities, with realized and unrealized gains of $1.1 million in fiscal year 2024, compared to $51,000 in fiscal year 2023 [1, 9].

A significant factor affecting the company's income tax expense was the change in Florida's revenue apportionment methodology, which resulted in a $1.3 million tax expense [1, 2].

Cryo-Cell International, Inc. (CCEL) Debt vs. Equity Structure

Understanding how Cryo-Cell International, Inc. (CCEL) finances its growth involves examining its debt and equity structure. This includes analyzing the levels of debt the company holds, its debt-to-equity ratio, and any recent activities related to debt.

As of the fiscal year 2024, Cryo-Cell International, Inc. (CCEL) has a noteworthy debt profile. According to their balance sheets:

• The company's total liabilities amounted to $7,599,000.
• Specifically, the total current liabilities stood at $6,687,000.
• Total long-term debt was reported as $912,000.

The debt-to-equity ratio is a critical metric for evaluating a company's financial leverage. It indicates the proportion of equity and debt a company uses to finance its assets. As of the most recent data, Cryo-Cell International, Inc.'s (CCEL) debt-to-equity ratio can be analyzed in the context of its total equity and total liabilities.

Based on the balance sheet data:

• Total Stockholder Equity was $35,444,000.

The debt-to-equity ratio is calculated as Total Liabilities divided by Total Stockholder Equity. For Cryo-Cell International, Inc. (CCEL), this would be $7,599,000 / $35,444,000, resulting in a ratio of approximately 0.21. This indicates that for every dollar of equity, Cryo-Cell International, Inc. (CCEL) has about 21 cents of debt. A lower ratio generally suggests less financial risk.

Here's a snapshot of Cryo-Cell International, Inc.'s (CCEL) balance sheet figures:

Balancing debt and equity is crucial for sustainable growth. Too much debt can increase financial risk, while too little debt might indicate that a company is not taking advantage of leverage to enhance returns. Cryo-Cell International, Inc. (CCEL) appears to maintain a conservative approach with its debt levels, which could reflect a strategic decision to minimize financial risk and ensure long-term stability.

To gain further insights into the company's strategic direction, you might find this resource helpful: Mission Statement, Vision, & Core Values of Cryo-Cell International, Inc. (CCEL).

Cryo-Cell International, Inc. (CCEL) Liquidity and Solvency

Liquidity and solvency are vital indicators of a company's financial health, revealing its ability to meet short-term obligations and sustain long-term operations. For Cryo-Cell International, Inc. (CCEL), analyzing these metrics provides insights into its financial stability and risk profile. Let's delve into the key aspects of CCEL's liquidity.

Assessing Cryo-Cell International, Inc. (CCEL)'s Liquidity:

Understanding Cryo-Cell International, Inc. (CCEL)'s liquidity involves examining its current and quick ratios, working capital trends, and cash flow statements. These elements provide a comprehensive view of the company's ability to manage its short-term financial obligations.

• Current and Quick Ratios: These ratios measure a company's ability to pay off its current liabilities with its current assets. A higher ratio generally indicates better liquidity.
• Analysis of Working Capital Trends: Working capital, the difference between current assets and current liabilities, indicates the funds available for day-to-day operations. Monitoring its trends helps assess liquidity management.
• Cash Flow Statements Overview: Analyzing cash flow from operating, investing, and financing activities reveals the sources and uses of cash, offering insights into liquidity generation and management.

According to the data from Cryo-Cell International, Inc.'s Form 10-K filing for the fiscal year ended November 30, 2024, the company's financial position is as follows:

Based on the consolidated balance sheets, Cryo-Cell International, Inc. (CCEL) has total current assets of $27,185,760 and total current liabilities of $4,073,631 as of November 30, 2024. This suggests a strong liquidity position, as current assets significantly exceed current liabilities.

Potential Liquidity Concerns or Strengths:

Cryo-Cell International, Inc. (CCEL) exhibits a robust liquidity position, supported by a substantial amount of cash, cash equivalents, and marketable securities. However, monitoring working capital trends and cash flow dynamics is crucial for maintaining this strength. Here are some key considerations:

• Strengths: High levels of liquid assets provide a buffer against short-term financial obligations.
• Considerations: Effective management of accounts receivable and deferred revenue is essential for sustaining liquidity.

In summary, Cryo-Cell International, Inc. (CCEL) demonstrates a strong liquidity profile, underscored by its healthy current asset base and prudent management of liabilities. Continuous monitoring of key financial metrics will ensure the company remains well-positioned to meet its financial commitments and capitalize on growth opportunities.

Cryo-Cell International, Inc. (CCEL) Valuation Analysis

Determining whether Cryo-Cell International, Inc. (CCEL) is overvalued or undervalued requires a multifaceted approach, incorporating key financial ratios, stock performance analysis, and analyst opinions. Here’s a breakdown:

Valuation Ratios:

• Price-to-Earnings (P/E) Ratio: This ratio indicates how much investors are willing to pay for each dollar of earnings. A higher P/E ratio might suggest overvaluation, while a lower one could indicate undervaluation, relative to industry peers or historical averages.
• Price-to-Book (P/B) Ratio: The P/B ratio compares a company's market capitalization to its book value of equity. It can help investors determine whether they are paying too much for the net assets of the company.
• Enterprise Value-to-EBITDA (EV/EBITDA) Ratio: This ratio compares the total value of the company (enterprise value) to its earnings before interest, taxes, depreciation, and amortization (EBITDA). It provides a more comprehensive valuation measure than P/E, especially when comparing companies with different capital structures.

As of February 7, 2025, Simply Wall St. data indicates that Cryo-Cell International's P/E ratio stands at 73.3x, which is higher than the U.S. Healthcare industry average of 23.2x. This could suggest that the stock is currently overvalued compared to its peers. However, it’s crucial to consider future growth expectations and other factors before drawing a definitive conclusion.

Stock Price Trends:

• Analyzing the stock price movement over the past 12 months (or longer) can reveal trends and potential turning points.
• Significant price increases might reflect investor optimism, while declines could signal concerns about the company's future prospects.

Over the past year, Cryo-Cell International has shown substantial stock appreciation. As of February 7, 2025, the stock has increased by 43%. This growth may be attributed to increased investor confidence or specific company achievements during the period.

Dividend Yield and Payout Ratios:

• Dividend yield indicates the return on investment solely from dividends.
• Payout ratios show the proportion of earnings paid out as dividends, indicating the sustainability of dividend payments.

As of 2024, Cryo-Cell International does not offer a dividend. Therefore, dividend yield and payout ratios are not applicable in this valuation analysis.

Analyst Consensus:

• Professional analysts who cover Cryo-Cell International provide ratings (buy, hold, or sell) and price targets.
• These ratings represent the collective wisdom of experts and can influence investor sentiment.

Analyst ratings can offer valuable insights, but they should be viewed as one component of a comprehensive valuation analysis. As of February 7, 2025, the consensus among analysts is that the stock is a 'hold,' with a target price that suggests limited near-term upside. However, it’s essential to consider the range of individual analyst opinions and the factors driving their recommendations.

A comprehensive valuation would also consider qualitative factors, such as the company's competitive position, management quality, and industry outlook. Furthermore, it's important to understand Mission Statement, Vision, & Core Values of Cryo-Cell International, Inc. (CCEL).

Financial Snapshot:

Cryo-Cell International, Inc. (CCEL) Risk Factors

Understanding the risks associated with Cryo-Cell International, Inc. (CCEL) is crucial for investors. These risks can stem from both internal and external factors, impacting the company’s financial health and future performance. Here's an overview of potential challenges:

• Industry Competition: The cord blood and tissue banking industry is competitive. New entrants and existing players vying for market share could put pressure on Cryo-Cell's pricing and profitability.
• Regulatory Changes: Changes in regulations governing cord blood banking, both in the U.S. and internationally, could increase compliance costs or restrict certain business activities.
• Market Conditions: Economic downturns or shifts in consumer preferences could reduce demand for cord blood and tissue storage services.

Operational, financial, and strategic risks are also important to consider. These are often detailed in the company's filings. While specific, up-to-the-minute details from recent earnings reports are not available, here are some general areas to watch based on typical business risks:

• Operational Risks: These could include disruptions in laboratory operations, equipment failures, or issues with the collection, processing, and storage of cord blood and tissue. Maintaining high standards of quality control is essential.
• Financial Risks: These might involve fluctuations in revenue, increasing operating costs, or challenges in managing cash flow. The ability to maintain a healthy balance sheet is critical.
• Strategic Risks: These could relate to the company's ability to innovate, adapt to changing market conditions, or successfully execute its growth strategy.

Mitigation strategies are crucial for addressing these risks. While specific plans would be detailed in company reports, common strategies include:

• Diversification: Expanding service offerings or geographic reach to reduce reliance on a single market or product.
• Cost Management: Implementing measures to control operating expenses and improve efficiency.
• Compliance: Maintaining rigorous quality control standards and adhering to all applicable regulations.
• Innovation: Investing in research and development to develop new products and services.

For more insights, read the full analysis: Breaking Down Cryo-Cell International, Inc. (CCEL) Financial Health: Key Insights for Investors

Cryo-Cell International, Inc. (CCEL) Growth Opportunities

To understand Cryo-Cell International, Inc. (CCEL)'s potential trajectory, it's crucial to evaluate its key growth drivers, future financial forecasts, strategic initiatives, and competitive strengths. These elements combined provide a perspective on the company's capacity to expand and sustain its market position.

Key growth drivers for Cryo-Cell International, Inc. (CCEL) may include:

• Product Innovations: Continued advancements and diversification in stem cell storage and related services.
• Market Expansions: Extending its geographic footprint and targeting new customer segments.
• Acquisitions: Strategic acquisitions of complementary businesses to broaden its service offerings and market share.

Predicting future revenue growth and earnings requires considering various factors. While precise figures are subject to market dynamics, key indicators and strategic initiatives offer insights into potential financial performance. Keep in mind that as of the latest available data, specific revenue growth projections and earnings estimates for Cryo-Cell International, Inc. (CCEL) for the 2024 fiscal year are not available in the provided search results.

Strategic initiatives and partnerships can significantly influence Cryo-Cell International, Inc. (CCEL)'s growth. These may include:

• Collaborations with research institutions to enhance service offerings.
• Partnerships with healthcare providers to expand market reach.
• Investments in technology to improve operational efficiency and customer experience.

Cryo-Cell International, Inc. (CCEL)'s competitive advantages play a crucial role in its growth prospects. These advantages may include:

• Established Brand Reputation: A strong reputation for reliability and quality in stem cell storage.
• Proprietary Technology: Unique technologies or processes that provide a competitive edge.
• Customer Relationships: Strong relationships with healthcare providers and expectant parents.

For more detailed insights into Cryo-Cell International, Inc. (CCEL)'s financial health, you can explore: Breaking Down Cryo-Cell International, Inc. (CCEL) Financial Health: Key Insights for Investors